Iskra takes over Wang Lei soon, AstraZeneca China's senior management launches major personnel adjustments
白云追月素
发表于 6 天前
129
0
0
On the evening of December 4th, AstraZeneca announced several important personnel appointments. Among them, the positions of Global Executive Vice President and Head of International Business will be taken over by Iskra Reic. It is worth noting that Iskra is replacing Wang Lei, who had previously been temporarily absent from his job due to an investigation in China.
According to the data, Iskra joined AstraZeneca in 2001 and has since held various leadership positions within the company, including Global Executive Vice President, Head of Europe and Canada, and has been serving as Global Executive Vice President and Head of Vaccine and Immunotherapy Business since 2021. She has also held senior positions in Central and Eastern Europe, Eurasia, the Middle East, and Africa. Since 2017, Iskra has been a member of AstraZeneca's senior management team. Recently, Iskra has been responsible for the newly established AstraZeneca Vaccine and Immunotherapy Business Unit. In this position, she is fully responsible for the early and late development of the product pipeline and product portfolio, covering COVID-19 vaccine, respiratory syncytial virus vaccine and monoclonal antibody, strategic cooperation and acquisition, medical affairs and commercial operations.
AstraZeneca stated that after taking over, Iskra will be fully responsible for the overall strategy of this vast region, including China, Asia and Eurasia markets, the Middle East and Africa, Latin America, Australia and New Zealand, to drive sustainable business growth.
After the appointment of Iskra Reic was announced, the new international business leader quickly initiated a series of personnel adjustments to the management team in the China region. Specifically, according to information disclosed by AstraZeneca, the position of AstraZeneca China General Manager previously held by Lai Minglong will be taken over by Lin Xiao; The position of General Manager of AstraZeneca's China Oncology Business, concurrently held by Lai Minglong, will also be taken over by Guan Dongmei.
Meanwhile, Lin Xiao and Guan Dongmei will become members of the global management teams for the Biopharmaceutical Business Unit and the Oncology Business Unit, respectively. Lin Xiao, Guan Dongmei, and Hu Yiqing, Vice President of AstraZeneca China and Head of the Rare Disease Division, will all report directly to Iskra. After personnel changes, Lai Minglong will be transferred to the global oncology business unit of AstraZeneca, serving as the head of AstraZeneca's Dato DXd global oncology business and lung cancer business unit, reporting to Sunil Verma, the senior vice president and head of AstraZeneca's oncology business unit.
According to public information, before joining AstraZeneca, Lin Xiao served as the head of strategic planning for Asia and Greater China at Sanofi, the head of marketing for Sanofi's core product division in China, and also as the vice president of Ping An Good Doctor. Lin Xiao joined AstraZeneca in 2019 as the head of AstraZeneca's kidney treatment field in China. In January 2021, Lin Xiao will serve as the head of AstraZeneca's digital business in China on the basis of his original responsibilities, responsible for the development of digital, e-commerce and Internet hospital businesses. In February 2022, he became the Vice President of AstraZeneca China and the Head of the Respiratory, Digestive, and Autoimmune Business Unit. In August 2023, he became the Vice President of AstraZeneca China, responsible for the Respiratory Inhalation and Biopharmaceutical Division, as well as the Hong Kong and Macau regions.
Guan Dongmei has previously served as the head of the immune oncology business at Bristol Myers Squibb (BMS) and the head of the specialty drug division at GlaxoSmithKline (GSK). In November 2022, Guan Dongmei joined AstraZeneca as the head of the Cardiovascular, Renal, and Metabolic Division.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Douyu responds to changes in internal organizational structure: it is a normal personnel adjustment
- Fan Hua serves as the head of BlackRock China and Zhang Pengjun takes over as the sub general manager of financial management
- Jingke Energy: Holding high-level talks with China Huaneng Group to further deepen cooperation
- Election suspense resurfaces! Harris raises $200 million in first week to take over, with approval ratings on par with Trump
- MNC interim report scan | K-drug generates over $14.2 billion in revenue, HPV growth is weak, Merck urgently needs the next 'internet celebrity' successor
- Qian Yujun will step down as President and Vice Chairman of UBS China, and Hu Zhigui will take over
- Liu Qiangdong, taking over billions of Dada orders
- Industry reports suggest that ASML and TSMC executives will engage in equipment procurement negotiations for 2025. ASML plans to increase prices by 3-5%
- AstraZeneca China personnel adjustment, Lin Xiao as the general manager of AstraZeneca China
- Ant Group CFO Han Xinyi will take over as CEO from Jing Xiandong
-
10月末に2800ドルのマイルストーンを突破した後、国際金価格は短い調整を経た。 11日のニューヨーク商品取引所で来年2月に引き渡されたCOMEX金先物は1.5%近く上昇し、2750ドルの関門を再び奪還し、最新のインフレデ ...
- 什么大师特
- 7 小时前
- 支持
- 反对
- 回复
- 收藏
-
米大統領選後の株式市場の上昇は年末まで続いており、ウォール街の大物たちが叫んだ来年の目標価格も年々上昇しているが、上昇を追う際にはすべての慎重さを捨ててはならないと警告するアナリストも少なくない。 一 ...
- SOHU
- 昨天 11:47
- 支持
- 反对
- 回复
- 收藏
-
12月10日夜、米株が取引を開始し、市場の注目はグーグルに集中し、終値までにグーグルA(GOOGL)は5.59%上昇し、185.17ドルだった。その時価総額は一夜にして1120億ドル(約8120億元)も大幅に増加した。 情報面で ...
- 内托体头
- 昨天 11:15
- 支持
- 反对
- 回复
- 收藏
-
①北京時間の今夜21時30分に発表された米国の11月CPIデータを、「2024年最後の重量級の米国経済指標」にたとえても、誇張ではないようだ。②FRBが来週12月の金利決定会合を開催するにあたり、今晩のCPIもFRBが金利 ...
- 不正经的工程师
- 昨天 10:29
- 支持
- 反对
- 回复
- 收藏